Dunsire Takes XTuit Helm As First Targets Approach The Clinic
Executive Summary
The privately-held biopharma, focused on fibrotic diseases and cancer, appointed oncology veteran Deborah Dunsire as president and CEO as the firm’s first drug candidates mature toward the clinic.
You may also be interested in...
XTuit Believes Microenvironment Approach Will Yield Cancer And Fibrosis Therapies
Coming out of stealth with a $22 million Series A round, the biotech thinks its therapies targeting abnormal stroma could improve the activity of checkpoint inhibitors in cancer combo therapy and possibly reverse fibrosis in advanced liver disease.
Merck & Co. Buys Pandion, Building Out Capability In Autoimmune Disease
Merck & Co. reached a deal to acquire the developer of targeted immune modulators for $1.85bn. Pandion CEO Kakkar talked to Scrip about the acquisition.
High Deal Valuations & Volumes Will Persist, Industry Dealmakers Predict
Big pharma business development executives forecast a competitive and active deal-making year ahead for the industry at the Biocom partnering conference.
Need a specific report? 1000+ reports available
Buy Reports